Annovis Bio's Phase 2a trial of Posiphen (ANVS401) is now recruiting PwPs (USA)
Annovis is attempting to lessen a-synuclein-induced pathogenesis by reducing the synthesis of the a-synuclein protein.
PNT article: First Patients Dosed in Clinical Trial Investigating ANVS401 as Treatment for Parkinson's and Alzheimer's First Patients Dosed in ANVS4 1 Trial for Treating Parkinson's, Alzheimer's Trial Record: Posiphen Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients https://clinicaltrials.gov/ct2/show/NCT04524351 SoPD blog post (background info): Disney's "Attack of the synucleozid from Jupiter" Disney’s “Attack of the synucleozid from Jupiter” – The Science of Parkinson's Posiphen (ANVS401) mode of action: Posiphen is an orally available small molecule drug that inhibits the translation of a-synuclein, by increasing the affinity of Iron Regulatory Protein-1 (IRP1) to the Iron-Response Element (IRE) of the SNCA gene's messenger RNA (mRNA). This represses translation by preventing the association of the mRNA with the ribosome. |
ANVS401 phase 2a trial update
Dosing has now been completed in Annovis Bio's Phase 2a Trial of Posiphen (ANVS401).
PNT article: Dosing Finished in Phase 2a Trial of ANVS401 for Parkinson's, Alzheimer's This Phase 2a trial is described in the study record as a trial in two parts. The first part has 14 early PD patients and 14 early AD patients, taking either 80 mg daily of ANVS401 or placebo. Patient involvement in part 1 has been completed, and some interim results have been announced. The second part has 40 early PD patients taking 5 mg, 10 mg, 20 mg or 40 mg (no placebo). Patient involvement in part 2 has now also been completed. Some commentators regard the (early) release of interim data from part 1 as "drip feeding" results from an ongoing trial. For example, see this SoPD blog post comment from Simon: Monthly Research Review – June 2021 – The Science of Parkinson's Personally, I'm giving them the benefit of the doubt. |
All times are GMT -5. The time now is 04:56 PM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.